PMC6413441_01
Rapid SCORAD improvement and corticosteroid tapering in regards to Omalizumab therapy
12948_2019_109_Fig1_HTML.jpg
PMC6413441_01_12948_2019_109_Fig1_HTML.jpg
Fig1
Unexpectedly, clinical results were observed after just about 2 months of treatment as confirmed by a SCORAD of 1, and a clear improvement of QoL (Fig. 1).
Patient at T0 and after two months of Omalizumab treatment
12948_2019_109_Fig2_HTML.jpg
PMC6413441_01_12948_2019_109_Fig2_HTML.jpg
Fig2
After 1 year of Omalizumab treatment, the patient maintains a good control for both skin and gastrointestinal symptoms (Fig. 2).